Business
Nkarta Reports Second Quarter 2021 Financial Results and Business Progress
Initial data from NKX101 clinical trial expected by end of 2021NKX019 patient dosing expected to start in 2H 2021Collaboration with CRISPR Therapeutics to
About this update from Nkarta, Inc.
[{"type":"text","content":"Initial data from NKX101 clinical trial expected by end of 2021NKX019 patient dosing expected to start in 2H 2021Collaboration with CRISPR Therapeutics to develop gene-edited cell therapiesNew lease for commercial manufacturing center / headquarters to support rapid innovation and scaled production of NK cell therapies SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the second quarter ended June 30, 2021. “Nkarta continues to set the pace for NK cell therapy as we build on the strengths of our next generation platform and advance our two co-lead clinical programs,” said Paul J. Hastings, President and Chief Executive Officer of Nkarta. “During the period, we initiated collaboration activities with CRISPR Therapeutics, added new platform capabilities for rapid innovation, and expanded our manufacturing footprint – all designed to stay ahead of the technology curve and transform the scientific insights of cell therapy into meaningful medicines for cancer patients. Nkarta remains on track to report initial clinical data from our Phase 1 study of NKX101 by the end of this year.” RECENT ACCOMPLISHMENTS AND FUTURE MILESTONES NKX101 Nkarta aims to present initial clinical data from its ongoing clinical trial of NKX101 by year end 2021. In the Phase 1 study, patients receive multiple doses of NKX101 during a 28-day treatment cycle and are eligible to receive subsequent cycles of treatment upon evidence of tolerability and disease response. NKX019 Nkarta expects patient dosing in a Phase 1 clinical trial of NKX019 to initiate in the second half of 2021 and has begun manufacturing of clinical supply of NKX019 at its in-house cGMP clinical manufacturing facility in South San Francisco, California. Manufacturing Nkarta entered a lease agreement to establish a combined manufacturing facility and company headquarters. The manufacturing facility will produce materials for potential pivotal trials and commercial launch of multiple engineered NK cell therapy products. The expanded manufacturing footprint, centered in South San Francisco, California, builds upon Nkarta’s existing 2,700 square foot cGMP clinical manufacturing facility. Pipeline and Platform In May 202...